These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
171 related articles for article (PubMed ID: 38498991)
1. Potential of Thermal Ablation Combined with Immunotherapy in Peripheral Lung Tumors: A Review and Prospect. Yang R; Gu C; Xie F; Hong S; Herth FJF; Sun J Respiration; 2024; 103(6):295-316. PubMed ID: 38498991 [TBL] [Abstract][Full Text] [Related]
3. Percutaneous thermal ablation of lung tumors - Radiofrequency, microwave and cryotherapy: Where are we going? Palussière J; Catena V; Buy X Diagn Interv Imaging; 2017 Sep; 98(9):619-625. PubMed ID: 28844613 [TBL] [Abstract][Full Text] [Related]
4. [Current Status and Progress of Thermal Ablation Combined with Immunotherapy for Lung Tumors]. Liu B Zhongguo Fei Ai Za Zhi; 2022 Apr; 25(4):266-271. PubMed ID: 35477191 [TBL] [Abstract][Full Text] [Related]
5. Irreversible Electroporation: An Emerging Immunomodulatory Therapy on Solid Tumors. Zhang N; Li Z; Han X; Zhu Z; Li Z; Zhao Y; Liu Z; Lv Y Front Immunol; 2021; 12():811726. PubMed ID: 35069599 [TBL] [Abstract][Full Text] [Related]
13. Clinical application status and prospect of the combined anti-tumor strategy of ablation and immunotherapy. Yin L; Li XY; Zhu LL; Chen GL; Xiang Z; Wang QQ; Bi JW; Wang Q Front Immunol; 2022; 13():965120. PubMed ID: 36131929 [TBL] [Abstract][Full Text] [Related]
14. Sustained release of anti-PD-1 peptide for perdurable immunotherapy together with photothermal ablation against primary and distant tumors. Luo L; Yang J; Zhu C; Jiang M; Guo X; Li W; Yin X; Yin H; Qin B; Yuan X; Li Q; Du Y; You J J Control Release; 2018 May; 278():87-99. PubMed ID: 29626502 [TBL] [Abstract][Full Text] [Related]
15. Contribution of immune cells in synergistic anti-tumor effect of ablation and immunotherapy. He N; Jiang J Transl Oncol; 2024 Feb; 40():101859. PubMed ID: 38070356 [TBL] [Abstract][Full Text] [Related]
16. Cryoimmunotherapy with local co-administration of ex vivo generated dendritic cells and CpG-ODN immune adjuvant, elicits a specific antitumor immunity. Alteber Z; Azulay M; Cafri G; Vadai E; Tzehoval E; Eisenbach L Cancer Immunol Immunother; 2014 Apr; 63(4):369-80. PubMed ID: 24452202 [TBL] [Abstract][Full Text] [Related]
17. Distinct immune signatures in directly treated and distant tumors result from TLR adjuvants and focal ablation. Chavez M; Silvestrini MT; Ingham ES; Fite BZ; Mahakian LM; Tam SM; Ilovitsh A; Monjazeb AM; Murphy WJ; Hubbard NE; Davis RR; Tepper CG; Borowsky AD; Ferrara KW Theranostics; 2018; 8(13):3611-3628. PubMed ID: 30026870 [TBL] [Abstract][Full Text] [Related]
18. Locally Advanced Pancreatic Cancer: Percutaneous Management Using Ablation, Brachytherapy, Intra-arterial Chemotherapy, and Intra-tumoral Immunotherapy. Timmer FEF; Geboers B; Nieuwenhuizen S; Schouten EAC; Dijkstra M; de Vries JJJ; van den Tol MP; de Gruijl TD; Scheffer HJ; Meijerink MR Curr Oncol Rep; 2021 Apr; 23(6):68. PubMed ID: 33864144 [TBL] [Abstract][Full Text] [Related]
19. Bronchoscopic Ablative Therapies for Malignant Central Airway Obstruction and Peripheral Lung Tumors. Chaddha U; Hogarth DK; Murgu S Ann Am Thorac Soc; 2019 Oct; 16(10):1220-1229. PubMed ID: 31194922 [TBL] [Abstract][Full Text] [Related]
20. More than just tumor destruction: immunomodulation by thermal ablation of cancer. Haen SP; Pereira PL; Salih HR; Rammensee HG; Gouttefangeas C Clin Dev Immunol; 2011; 2011():160250. PubMed ID: 22242035 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]